2018 Q4 Form 10-K Financial Statement

#000167479619000049 Filed on April 02, 2019

View on sec.gov

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Entity File Number EntityFileNumber	000-15303
CY2018	dei	Entity Registrant Name EntityRegistrantName	HST GLOBAL, INC.
CY2018	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Nevada
CY2018	dei	Entity Address Address Line1 EntityAddressAddressLine1	150 Research Drive
CY2018	dei	Entity Address City Or Town EntityAddressCityOrTown	Hampton
CY2018	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2018	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	23666
CY2018	dei	City Area Code CityAreaCode	757
CY2018	dei	Local Phone Number LocalPhoneNumber	766-6100
CY2018Q4	dei	Entity Public Float EntityPublicFloat	87101	usd
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36719854	shares
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291	usd
CY2018Q4	us-gaap	Assets Current AssetsCurrent	0	usd
CY2017Q4	us-gaap	Assets Current AssetsCurrent	291	usd
CY2018Q4	us-gaap	Assets Assets	0	usd
CY2017Q4	us-gaap	Assets Assets	291	usd
CY2018Q4	us-gaap	Bank Overdrafts BankOverdrafts	2957	usd
CY2017Q4	us-gaap	Bank Overdrafts BankOverdrafts	0	usd
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3228	usd
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4688	usd
CY2018Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	505959	usd
CY2017Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	505959	usd
CY2018Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	1110000	usd
CY2017Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	990000	usd
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	376629	usd
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	340881	usd
CY2018Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1372169	usd
CY2017Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1351369	usd
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3370942	usd
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3192898	usd
CY2018Q4	us-gaap	Liabilities Liabilities	3370942	usd
CY2017Q4	us-gaap	Liabilities Liabilities	3192898	usd
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36719854	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36719854	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36719854	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36719854	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	36720	usd
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	36720	usd
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2384824	usd
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2384824	usd
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5792486	usd
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5614151	usd
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-3370942	usd
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-3192607	usd
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	0	usd
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	291	usd
CY2018	us-gaap	Revenues Revenues	0	usd
CY2017	us-gaap	Revenues Revenues	0	usd
CY2018	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	120000	usd
CY2017	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	120000	usd
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22587	usd
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32995	usd
CY2018	us-gaap	Operating Expenses OperatingExpenses	142587	usd
CY2017	us-gaap	Operating Expenses OperatingExpenses	152995	usd
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-142587	usd
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-152995	usd
CY2018	us-gaap	Interest Expense InterestExpense	-35748	usd
CY2017	us-gaap	Interest Expense InterestExpense	-35748	usd
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23651	usd
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35748	usd
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12097	usd
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-178335	usd
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-165092	usd
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36719854	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36719854	shares
CY2018	us-gaap	Profit Loss ProfitLoss	-178335	usd
CY2017	us-gaap	Profit Loss ProfitLoss	-165092	usd
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23651	usd
CY2018	us-gaap	Increase Decrease In Book Overdrafts IncreaseDecreaseInBookOverdrafts	-2957	usd
CY2017	us-gaap	Increase Decrease In Book Overdrafts IncreaseDecreaseInBookOverdrafts	0	usd
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1461	usd
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3121	usd
CY2018	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	120000	usd
CY2017	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	120000	usd
CY2018	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	35748	usd
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	35748	usd
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21091	usd
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29874	usd
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2018	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	20800	usd
CY2017	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	29700	usd
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20800	usd
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29700	usd
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-291	usd
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-174	usd
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291	usd
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	465	usd
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291	usd
CY2018	us-gaap	Interest Paid InterestPaid	0	usd
CY2017	us-gaap	Interest Paid InterestPaid	0	usd
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt"><b>NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES</b></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">HST Global, Inc. (“the Company”) was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc. At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">HST Global, Inc. is an integrated Health and Wellness Biotechnology company that is developing and/or acquiring a network of Wellness Centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases.  In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases.</p>
CY2018	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify"><span style="border-bottom:1px solid #000000">Basis of Presentation</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying consolidated financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K.  </p>
CY2018	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-37450	usd
CY2017	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-56131	usd
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	37450	usd
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	56131	usd
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify"><span style="border-bottom:1px solid #000000">Use of Estimates</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2018	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	20800	usd
CY2017	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	29700	usd
CY2018Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1372169	usd
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	-1237814	usd
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	-1934445	usd
CY2018Q4	us-gaap	Income Tax Effects Allocated Directly To Equity IncomeTaxEffectsAllocatedDirectlyToEquity	113692	usd
CY2017Q4	us-gaap	Income Tax Effects Allocated Directly To Equity IncomeTaxEffectsAllocatedDirectlyToEquity	184072	usd
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1124122	usd
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1759373	usd
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd

Files In Submission

Name	View Source	Status
0001674796-19-000049-index-headers.html	Edgar Link	pending
0001674796-19-000049-index.html	Edgar Link	pending
0001674796-19-000049.txt	Edgar Link	pending
0001674796-19-000049-xbrl.zip	Edgar Link	pending
exhibit31-1.htm	Edgar Link	pending
exhibit31-2.htm	Edgar Link	pending
exhibit32-1.htm	Edgar Link	pending
exhibit32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hstc-20181231.htm	Edgar Link	pending
hstc-20181231.xsd	Edgar Link	pending
hstc201812311.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hstc-20181231_cal.xml	Edgar Link	unprocessable
hstc-20181231_def.xml	Edgar Link	unprocessable
hstc-20181231_htm.xml	Edgar Link	completed
hstc-20181231_lab.xml	Edgar Link	unprocessable
hstc-20181231_pre.xml	Edgar Link	unprocessable